BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15643668)

  • 1. What have animal models taught us about the p53 pathway?
    Lozano G; Zambetti GP
    J Pathol; 2005 Jan; 205(2):206-20. PubMed ID: 15643668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To die or not to die: how does p53 decide?
    Slee EA; O'Connor DJ; Lu X
    Oncogene; 2004 Apr; 23(16):2809-18. PubMed ID: 15077144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the Arf/p53 tumor surveillance network by E2F.
    Iaquinta PJ; Aslanian A; Lees JA
    Cold Spring Harb Symp Quant Biol; 2005; 70():309-16. PubMed ID: 16869767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of p53 activation--spoilt for choice.
    Vousden KH
    J Cell Sci; 2006 Dec; 119(Pt 24):5015-20. PubMed ID: 17158908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
    Lane DP
    Cold Spring Harb Symp Quant Biol; 2005; 70():489-97. PubMed ID: 16869788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living with p53, dying of p53.
    Aylon Y; Oren M
    Cell; 2007 Aug; 130(4):597-600. PubMed ID: 17719538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 alterations in human cancer: more questions than answers.
    Soussi T
    Oncogene; 2007 Apr; 26(15):2145-56. PubMed ID: 17401423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 pathway.
    Prives C; Hall PA
    J Pathol; 1999 Jan; 187(1):112-26. PubMed ID: 10341712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation.
    Pérez de Castro I; Benet M; Jiménez M; Alzabin S; Malumbres M; Pellicer A
    Cancer Res; 2005 Apr; 65(8):3249-56. PubMed ID: 15833857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetics of the p53 pathway, apoptosis and cancer therapy.
    Vazquez A; Bond EE; Levine AJ; Bond GL
    Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Of flies and men; p53, a tumour suppressor.
    Sutcliffe JE; Brehm A
    FEBS Lett; 2004 Jun; 567(1):86-91. PubMed ID: 15165898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
    Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
    Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression.
    Efeyan A; Collado M; Velasco-Miguel S; Serrano M
    Oncogene; 2007 Mar; 26(11):1645-9. PubMed ID: 16964282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-Dependent and -independent functions of the Arf tumor suppressor.
    Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
    Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
    Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
    Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
    Donninger H; Binder A; Bohm L; Parker MI
    Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The subcellular distribution of the p53 tumour suppressor, and organismal ageing.
    Wesierska-Gadek J; Schmid G
    Cell Mol Biol Lett; 2005; 10(3):439-53. PubMed ID: 16217555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.